Global Women’s Health Technology Market Size study & Forecast, by Technology type (Surgical, Diagnostic, Contraceptive, Labor & Delivery, Critical Care), By Indication (Cancer, Infertility, Menstruation, Pregnancy, Post-menopausal Syndrome, Pelvic Disorde

Global Women’s Health Technology Market Size study & Forecast, by Technology type (Surgical, Diagnostic, Contraceptive, Labor & Delivery, Critical Care), By Indication (Cancer, Infertility, Menstruation, Pregnancy, Post-menopausal Syndrome, Pelvic Disorders, Infectious Diseases), By End Users (Hospitals, Obstetrics & Gynaecology Clinics, Diagnostics Laboratory, Ambulatory Surgery Centers (ASC)), and Regional Analysis, 2022-2029

Global Women’s Health Technology Market is valued at approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XXX over the forecast period 2022-2029. Women's health technology refers to the use of medical devices, software, and digital tools that are specifically designed to address women's unique health needs. It encompasses a wide range of technologies that can help women manage their health, including tools for reproductive health, menstrual cycle tracking, breast health, menopause, pregnancy, and more. These technologies are designed to provide women with personalized and effective healthcare solutions that cater to their specific needs and empower them to take control of their health and well-being. The market demand is primarily driven by the factors such as increased awareness and demand for personalized healthcare, greater emphasis on preventative healthcare by providing tools for early detection and prevention of health issues which prevent the onset of chronic diseases.

In addition, with increasing female presence in healthcare as providers, researchers, and innovators, there is a growing emphasis on addressing women's specific health needs. This has led to increased investment and development of women's health technology. According to World Health Organization (WHO), Women make approximately 67% of the worldwide health and social care workforce. It is estimated that women provide significant health services to around 5 billion people worldwide. Women's contributions to health-care systems are estimated to be worth more than USD 3 trillion every year. Furthermore, the increasing investments towards the research & development of women’s health, as well as the development of new diagnostic and treatment technologies are presenting lucrative opportunities for market growth over the forthcoming years. However, regulatory processes could be time-consuming and expensive which can limit the investment for new products, that is restricting the market growth over the forecast period of 2022-2029.

The key regions considered for the Global Women’s Health Technology Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the substantial investments made by the major businesses in the invention of creative solutions and technologies for women's health. Also, the prevalence of disorders including post-menopausal syndromes, breast cancer, pelvic or ureteral cancer, and others are rising. Whereas, Asia Pacific is also expected to grow at the highest growth rate over the forecasting period. Factors such as the increase in birth rates, more knowledge of women's health technology, and other health concerns are burgeoning the market growth in the forecasting years.

Major market players included in this report are:
Chiaro Technology Ltd
NaturalCycles Nordic AB
Ava Science Inc.
UE LifeSciences Inc.
Aspect Imaging Ltd.
Celmatix Inc.
Assurex Health Inc.
Rho Capital Partners
Evofem Biosciences Inc.
Embr Labs

Recent Developments in the Market:
 In October 2022, Iraq and Afghanistan Veterans of America (IAVA), the main voice of the post-9/11 generation of veterans, is delighted to announce its new relationship with Assurex Health, which is now Myriad Neuroscience Genetics, Inc., a leading genetic testing and precision medicine firm. The GeneSight® test is available to assist doctors to understand how a patient's genes may influence how they metabolise and/or respond to certain drugs routinely used for depression, anxiety, ADHD, and other mental illnesses.
 In November 2021, Ava, the first FDA-cleared fertility tracking wearable, announced that it will now be available as a workplace family-building benefit support tool through a partnership with WINFertility (WIN), the nation's leading fertility benefits management company with the largest employer client portfolio. The collaboration will enable WIN to make the Ava bracelet available to its members, providing an alternative route to data-driven technology that boosts the possibilities of natural conception.

Global Women’s Health Technology Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Technology type, Indication, End Users, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Technology type:
Surgical
Diagnostic
Contraceptive
Labor & Delivery
Critical Care

By Indication:
Cancer
Infertility
Menstruation
Pregnancy
Post-menopausal Syndrome
Pelvic Disorders
Infectious Diseases

By End Users:
Hospitals
Obstetrics & Gynaecology Clinics
Diagnostics Laboratory
Ambulatory Surgery Centers (ASC)

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
ROLA
Rest of the World




Companies Mentioned

Chiaro Technology Ltd
NaturalCycles Nordic AB
Ava Science Inc.
UE LifeSciences Inc.
Aspect Imaging Ltd.
Celmatix Inc.
Assurex Health Inc.
Rho Capital Partners
Evofem Biosciences Inc.
Embr Labs

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.